Faeth Therapeutics, Inc. Total Liabilities and Equity
Faeth Therapeutics, Inc. (FTH) had Total Liabilities and Equity of $189.31 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Balance Sheet
us-gaap:LiabilitiesAndStockholdersEquity · last filed 2026-08-04
- 2026-06-30: Liabilities and Equity $189.31M.
- 2026-03-31: Liabilities and Equity $205.38M.
- 2025-12-31: Liabilities and Equity $22.90M.
- 2025-09-30: Liabilities and Equity $27.59M.
| Period end | Liabilities and Equity |
|---|---|
| 2026-06-30 | $189.31M 10-Q · filed 2026-08-04 |
| 2026-03-31 | $205.38M 10-Q · filed 2026-05-15 |
| 2025-12-31 | $22.90M 10-Q · filed 2026-08-04 |
| 2025-09-30 | $27.59M 10-Q · filed 2025-11-14 |
| 2025-06-30 | $31.78M 10-Q · filed 2025-08-05 |
| 2025-03-31 | $38.27M 10-Q · filed 2025-05-06 |
| 2024-12-31 | $45.36M 10-K · filed 2026-03-30 |
| 2024-09-30 | $53.25M 10-Q · filed 2024-11-14 |
| 2024-06-30 | $59.80M 10-Q · filed 2024-08-06 |
| 2024-03-31 | $66.69M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $74.37M 10-K · filed 2025-03-28 |
| 2023-09-30 | $81.66M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $89.58M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $107.93M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $118.38M 10-K · filed 2024-02-29 |
| 2022-09-30 | $128.80M 10-Q · filed 2022-11-08 |
| 2022-06-30 | $138.04M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $150.04M 10-Q · filed 2022-05-10 |
| 2021-12-31 | $153.22M 10-K · filed 2023-03-29 |
| 2021-09-30 | $161.25M 10-Q · filed 2021-11-10 |
| 2021-06-30 | $167.72M 10-Q · filed 2021-08-11 |
| 2021-03-31 | $174.48M 10-Q · filed 2021-05-13 |
| 2020-12-31 | $21.43M 10-K · filed 2022-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |